Arvinas Stock (NASDAQ:ARVN)
Previous Close
$6.95
52W Range
$5.94 - $37.38
50D Avg
$12.81
200D Avg
$21.43
Market Cap
$508.91M
Avg Vol (3M)
$2.17M
Beta
2.32
Div Yield
-
ARVN Company Profile
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
ARVN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVMD | Revolution Medicines, Inc. |
| FHTX | Foghorn Therapeutics Inc. |
| CCCC | C4 Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| KURA | Kura Oncology, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| STTK | Shattuck Labs, Inc. |